Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Gossamer Bio Inc (4GB.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
2.1400-6.8100 (-76.09%)
At close: 09:01PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.9500
Open8.7000
Bid2.2200 x N/A
Ask2.3000 x N/A
Day's Range2.1400 - 8.7000
52 Week Range2.1400 - 15.0000
Volume500
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 01, 2023 - Mar 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 4GB.DU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis

      BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu

    • Benzinga

      Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

      Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib ar

    • MarketWatch

      Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

      Shares of Gossamer Bio Inc. plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s sotatercept. "We expect the street to be disappointed in these topline results given both

    Advertisement
    Advertisement